ReviewAnnals of translational medicine2020
Engineering better stem cell therapies for treating heart diseases.
Review in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Induced pluripotent stem cell therapies in heart failure treatment: a meta-analysis and systematic review.Regenerative medicinePooled it
- Stromal-platelet membrane-inspired nanoparticles (SPIN) for targeted heart repair.Bioactive materials · 2025Article
- Comparison of Conventional Therapies With Stem Cell Therapy in the Treatment of Heart Disease.Cureus · 2025Article
- Sexual Dimorphism in Cardiometabolic Diseases: From Development to Senescence and Therapeutic Approaches.Cells · 2025Review
- Extracellular vesicle therapeutics for cardiac repair.Journal of molecular and cellular cardiology · 2025Review
- Contemporary Challenges of Regenerative Therapy in Patients with Ischemic and Non-Ischemic Heart Failure.Journal of cardiovascular development and disease · 2022Review
- Overexpression of integrin βAnnals of translational medicine · 2022Article
- Advances in biomaterials and regenerative medicine for primary ovarian insufficiency therapy.Bioactive materials · 2021Review
- All Roads Lead to Rome (the Heart): Cell Retention and Outcomes From Various Delivery Routes of Cell Therapy Products to the Heart.Journal of the American Heart Association · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
For decades, stem cells and their byproducts have shown efficacy in repairing tissues and organs in numerous pre-clinical studies and some clinical trials, providing hope for possible cures for many important diseases. However, the translation of stem cell therapy for heart diseases from bench to bed is still hampered by several limitations. The therapeutic benefits of stem cells are mediated by a combo of mechanisms. In this review, we will provide a brief summary of stem cell therapies for ischemic heart disease. Basically, we will talk about these barriers for the clinical application of stem cell-based therapies, the investigation of mechanisms behind stem-cell based cardiac regeneration and also, what bioengineers can do and have been doing on the translational stage of stem cell therapies for heart repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.